First affected person dosed with VMT01 in a section 1/2a trial to judge its security in sufferers with metastatic melanoma, together with Opdivo.The...
Sonnet BioTherapeutics studies optimistic security outcomes from a section 1 trial of SON-1010 mixed with trabectedin for superior leiomyosarcoma or liposarcoma, with no...